摘要:
The subject invention is directed to methods of treating cardiac pacing dysfunction by administering HCN genes, alone or in combination with other genes.
摘要:
Novel oligonucleotides and methods of treating a cardiac disease or disorder using the same are provided. The oligonucleotides are useful in modulating the expression of the connexin 43 protein and may be combined with other biologically active agents and compositions to treat cardiac disease. Methods of modulating connexin expression include the suppression of the expression of connexin 43 and the inducement of expression of connexin 45.
摘要:
Electrical medical leads having active fixation electrodes, particularly helix electrodes intended to be screwed into body tissue, e.g., the heart, are disclosed having selectively applied insulation to optimize exposed electrode surface area and dispose the exposed electrode surface area toward tissue that is less traumatized by injury caused by screwing in the fixation helix. In a preferred fabrication method, an outer helical surface is masked by contact with a masking tube while a dielectric coating is applied to the inner helical surface of the coil turns of the helix, and the masking tube is removed when the dielectric coating has set. In one variation, at least one aperture is formed through the masking tube sidewall exposing an area of the outer helical surface thereby interrupting the uninsulated outer helical electrode.
摘要:
The present invention is directed toward methods for regulating biological pacemaking activity and devices used in such regulation. Such regulation can be accomplished by introducing genetic material to the heart by transfecting heart cells of the atrium or ventricle with an oligonucleotide, small interfering RNA, that silence KCNJ2, and suppress the IK1 current. Suppression (or silencing) of KCNJ2 subsequently induces pacemaker-like activities in previously regular myocytes. This invention provides for methods of targeted delivery using a fluid delivery catheter. Such a catheter allows the targeting of a specific area in the atrium or the ventricle of the heart. Also, combination methods of treating arrhythmia with traditional device-based therapies (e.g., pacemakers and defibrillators) and an oligonucleotide of the subject invention.
摘要:
A therapy delivery and/or diagnostic device includes a layer of a catalytic agent, having nitrite reductase and/or nitrate reductase, or nitrosothiol reductase activity. The catalytic layer converts nitrate/nitrate or nitrosothiols to nitric oxide when in contact with blood.
摘要:
An electric dashboard actuator including an electric motor driving an indicator. The electric motor includes a hollow output shaft of which the ends are located at and flush with two opposite surfaces of the motor, and the indicator includes a male coupling member with a cross-section matching the cross-section of the hollow motor output shaft. One motor surface includes a male or female coupling perpendicular to the surface.
摘要:
A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要:
The subject invention is directed to methods of treating cardiac pacing dysfunction by administering HCN genes, alone or in combination with other genes.
摘要:
A dashboard indicator module including a rotating actuator including a hollow output shaft controlling movement of an indicator with a light conducting path, connected to a light source, diffusing a light at an angle, and a reduction gear set. The external diameter of the conducting path is between 2.6 and 5.5 millimeters.
摘要:
A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.